Neo Ivy Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Neo Ivy Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.24M	Buy	+53,149	New	+$1.15M	0.33%	115

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Neo Ivy Capital Management's SNDX Position: Q1 2026 in Review

Neo Ivy Capital Management opened a new position in Syndax Pharmaceuticals (SNDX) in Q1 2026: 53,149 shares worth $1.24M. The stake represents 0.33% of the portfolio and ranks #115 among its holdings.

247 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

Neo Ivy Capital Management held 53,149 shares of Syndax Pharmaceuticals worth $1.24M as of Q1 2026.
Syndax Pharmaceuticals was a new Neo Ivy Capital Management position in Q1 2026.
Syndax Pharmaceuticals made up 0.33% of Neo Ivy Capital Management's portfolio in Q1 2026, its #115 holding.
247 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Neo Ivy Capital Management's 13F filing for Q1 2026, filed 15 May 2026.